Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth.

Jin T, Fu J, Feng XJ, Wang SM, Huang X, Zhu MH, Zhang SH.

Cell Biol Int. 2013 Sep;37(9):929-39. doi: 10.1002/cbin.10113. Epub 2013 Apr 30.

PMID:
23589395
2.

ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth.

Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M.

PLoS One. 2011 Mar 15;6(3):e17794. doi: 10.1371/journal.pone.0017794.

3.

Clinicopathologic significance and function of S-phase kinase-associated protein 2 overexpression in hepatocellular carcinoma.

Zhang SH, Qian YM, Liu AW, Cai J, Zhao XL, Wei JJ, Zhu MH.

Hum Pathol. 2012 Jul;43(7):1084-93. doi: 10.1016/j.humpath.2011.08.019. Epub 2011 Dec 26.

PMID:
22204716
4.

Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.

Wei S, Xiong M, Zhan DQ, Liang BY, Wang YY, Gutmann DH, Huang ZY, Chen XP.

Carcinogenesis. 2012 Mar;33(3):538-47. doi: 10.1093/carcin/bgr319. Epub 2012 Jan 5.

5.

Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).

Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C, Shen A, Wang Y, Li C, Yuan Q, Chen H, Cheng C, He S.

Hum Pathol. 2013 Mar;44(3):365-73. doi: 10.1016/j.humpath.2012.03.030. Epub 2012 Sep 17.

PMID:
22995332
6.

DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.

Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, Wu Lee YH.

Oncogene. 2006 Mar 30;25(14):1991-2003.

PMID:
16301996
7.

HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression.

Liu YP, Yang XN, Jazag A, Pan JS, Hu TH, Liu JJ, Guleng B, Ren JL.

PLoS One. 2012;7(5):e36914. doi: 10.1371/journal.pone.0036914. Epub 2012 May 15.

8.

Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.

Wang Z, Wei W, Sun CK, Chua MS, So S.

Liver Int. 2015 Apr;35(4):1403-15. doi: 10.1111/liv.12651. Epub 2014 Aug 25.

PMID:
25098386
9.

miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.

Wang CM, Wang Y, Fan CG, Xu FF, Sun WS, Liu YG, Jia JH.

Biochem Biophys Res Commun. 2011 Aug 5;411(3):586-92. doi: 10.1016/j.bbrc.2011.06.191. Epub 2011 Jul 6.

PMID:
21763284
10.

RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.

Xue WJ, Li C, Zhou XJ, Guan HG, Qin L, Li P, Wang ZW, Qian HX.

J Gastroenterol Hepatol. 2008 Sep;23(9):1448-58. Epub 2007 Aug 6.

PMID:
17683489
12.

Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.

Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F, Pascale RM.

J Hepatol. 2011 Jul;55(1):111-9. doi: 10.1016/j.jhep.2010.10.031. Epub 2010 Dec 7.

PMID:
21419759
13.

P21WAF1/CIP1 messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinoma tissues.

Kobayashi S, Matsushita K, Saigo K, Urashima T, Asano T, Hayashi H, Ochiai T.

Cancer. 2001 Jun 1;91(11):2096-103.

PMID:
11391590
14.

Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.

Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J, Zheng SS.

PLoS One. 2010 Dec 29;5(12):e14460. doi: 10.1371/journal.pone.0014460.

15.

An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection.

Lin CL, Chien RN, Lin SM, Ke PY, Lin CC, Yeh CT.

PLoS One. 2013 May 29;8(5):e65456. doi: 10.1371/journal.pone.0065456. Print 2013.

16.

Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.

Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M.

Hepatology. 2003 May;37(5):1086-96.

PMID:
12717389
17.

Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma.

Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA, Zhuang H.

Cancer. 2012 May 1;118(9):2431-42. doi: 10.1002/cncr.26566. Epub 2011 Oct 11.

18.

Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.

Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, Fan D, Nie Y, Wu K.

J Hepatol. 2012 Sep;57(3):600-12. doi: 10.1016/j.jhep.2012.04.020. Epub 2012 May 18.

PMID:
22613004
19.

Down-regulation of Toll-like receptor 7 expression in hepatitis-virus-related human hepatocellular carcinoma.

Lin KJ, Lin TM, Wang CH, Liu HC, Lin YL, Eng HL.

Hum Pathol. 2013 Apr;44(4):534-41. doi: 10.1016/j.humpath.2012.06.015. Epub 2012 Oct 12.

PMID:
23069256
20.

Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection.

Tang SH, Yang DH, Huang W, Zhou M, Zhou HK, Lu XH, Ye G.

Cancer Detect Prev. 2006;30(2):192-203. Epub 2006 May 12.

PMID:
16697535
Items per page

Supplemental Content

Write to the Help Desk